Search research articles
Contact Us
Filters
Showing results (201-210 of 277) with videos related to
Page
of 28
Sort By:
Cancer Medicine
|
November 25, 2016
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
Zhijie Wang, Naiyi Shi, Aung Naing, et al.
Scientific Reports
|
October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
Vivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs
|
October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
Shumei Kato, Denis L Jardim, Faye M Johnson, et al.
Oncology
|
November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
Holly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Clinical Genitourinary Cancer
|
August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors
Denis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
JCO Precision Oncology
|
February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors
Morten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 277) with videos related to
Sort By:
Page
of 28
Cancer Medicine
|
November 25, 2016
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
Zhijie Wang, Naiyi Shi, Aung Naing, et al.
Scientific Reports
|
October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
Vivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs
|
October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
Shumei Kato, Denis L Jardim, Faye M Johnson, et al.
Oncology
|
November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
Holly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Clinical Genitourinary Cancer
|
August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors
Denis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
JCO Precision Oncology
|
February 16, 2022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors
Morten Lapin, Helen J Huang, Sharmeen Chagani, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2019
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S Falchook, Razelle Kurzrock, Hesham M Amin, et al.
Page
of 28